Media headlines about Cytokinetics, (NASDAQ:CYTK) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cytokinetics, earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 44.9097850833857 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

Shares of Cytokinetics, (NASDAQ CYTK) opened at 14.70 on Tuesday. Cytokinetics, has a one year low of $8.51 and a one year high of $17.20. The stock has a 50 day moving average of $13.49 and a 200 day moving average of $13.43. The stock’s market cap is $788.89 million.

Cytokinetics, (NASDAQ:CYTK) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by $0.03. The business had revenue of $3.05 million for the quarter, compared to analyst estimates of $5.28 million. Cytokinetics, had a negative return on equity of 14.15% and a negative net margin of 16.00%. Equities analysts expect that Cytokinetics, will post ($2.46) EPS for the current fiscal year.

Several brokerages have issued reports on CYTK. HC Wainwright set a $26.00 price objective on shares of Cytokinetics, and gave the stock a “buy” rating in a research report on Thursday, August 3rd. ValuEngine raised shares of Cytokinetics, from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub raised shares of Cytokinetics, from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. Cantor Fitzgerald reissued an “overweight” rating on shares of Cytokinetics, in a research report on Friday, May 19th. Finally, Morgan Stanley began coverage on shares of Cytokinetics, in a research report on Monday, July 31st. They set an “overweight” rating and a $24.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $21.30.

WARNING: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/09/12/cytokinetics-cytk-given-daily-news-impact-rating-of-0-12.html.

In other news, CEO Robert I. Blum sold 5,000 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $12.14, for a total transaction of $60,700.00. Following the completion of the transaction, the chief executive officer now owns 88,385 shares in the company, valued at $1,072,993.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Caryn Gordon Mcdowell sold 10,131 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $14.60, for a total transaction of $147,912.60. Following the transaction, the insider now owns 19,801 shares of the company’s stock, valued at approximately $289,094.60. The disclosure for this sale can be found here. Insiders have sold 164,809 shares of company stock valued at $2,412,572 in the last 90 days. Insiders own 7.20% of the company’s stock.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Insider Buying and Selling by Quarter for Cytokinetics, (NASDAQ:CYTK)

Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.